Tumors Clinical Trial
Official title:
Phase I Trial of RAD001C (Everolimus) in Pediatric Patients With Recurrent Refractory Solid Tumors or Brain Tumors
Patients with recurrent or refractory solid tumors or brain tumors that are unresponsive to conventional therapy, or with no known effective therapy, will be treated. Experiments in the laboratory have shown the experimental drug RAD001C (RAD001, Everolimus) can prevent cells from multiplying. RAD001 is now being tested in diseases such as cancer, in which excessive cell multiplication needs to be stopped. The drug has been tested in adult cancer patients and has been well tolerated by subjects in these studies. It is experimental and, therefore, available in clinical trials.
Although a Phase II portion of this study was planned, it was never initiated. ;
Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
Status | Clinical Trial | Phase | |
---|---|---|---|
Suspended |
NCT01562626 -
Phase I/II Study of APS001F With Flucytosine and Maltose in Solid Tumors
|
Phase 1/Phase 2 | |
Completed |
NCT00435669 -
A Phase I Study to Determine Absorption, Distribution, Metabolism, and Elimination of a Single Radiolabeled Dose of Brivanib (BMS-582664)
|
Phase 1 | |
Completed |
NCT00400023 -
A Phase 1, Open-Label, Randomized, Cross-Over, Pharmacokinetic Study Evaluating the Effect of S-1 on Advanced Solid Tumors
|
Phase 1 | |
Completed |
NCT00395434 -
Safety Study of Increasing Doses of Combretastatin in Combination With Bevacizumab (Avastin) in Patients With Advanced Solid Tumors
|
Phase 1 | |
Completed |
NCT00372437 -
A Phase I/II Study of MGCD0103 (MG-0103) in Combination With Gemcitabine
|
Phase 1/Phase 2 | |
Completed |
NCT00375245 -
Rapamycin With Grapefruit Juice for Advanced Malignancies
|
Phase 1 | |
Completed |
NCT00410696 -
Pegfilgrastim Versus Filgrastim After High-dose Chemotherapy
|
Phase 2 | |
Recruiting |
NCT00553033 -
Laparoscopic Liver Resection
|
N/A | |
Completed |
NCT00248404 -
NB1011 Administered by Continuous Infusion in Cancers That Overexpress Thymidylate Synthase (TS)
|
Phase 1/Phase 2 | |
Completed |
NCT00207103 -
MAD in Cancer Patients: Safety of BMS-582664 in Patients With Advanced or Metastatic Solid Tumors
|
Phase 1 | |
Completed |
NCT00222443 -
Pilot Study Combining Temozolomide, Oncovin, Camptosar and Oral Antibiotic in Children and Adolescents With Recurrent Malignancy
|
Phase 1 | |
Terminated |
NCT03251924 -
A Dose Escalation and Combination Immunotherapy Study to Evaluate BMS-986226 Alone or in Combination With Nivolumab or Ipilimumab in Patients With Advanced Solid Tumors
|
Phase 1/Phase 2 | |
Recruiting |
NCT05103969 -
Cohort of Tumors With POLE/D1 Mutation
|
||
Completed |
NCT00446446 -
PRISM (Panitumumab Regimen In Second-line Monotherapy of Head and Neck Cancer)
|
Phase 2 | |
Completed |
NCT02275910 -
Phase 1 Study of E7090 in Subjects With Solid Tumor
|
Phase 1 | |
Terminated |
NCT02271516 -
to evaluate188Re-BMEDA-liposome in Patient With Primary Solid Tumor in Advanced or Metastatic Stage
|
Phase 1 | |
Completed |
NCT01448759 -
Evaluation of Plasma Alcohol Concentration in Patients Receiving Paclitaxel or Docetaxel
|
N/A | |
Terminated |
NCT01081808 -
Laboratory-Treated Autologous Lymphocytes, Aldesleukin, and Sargramostim (GM-CSF) in Treating Advanced Solid Tumors
|
Phase 1 | |
Completed |
NCT00398814 -
Phase I Study of Perifosine + Sorafenib for Patients With Advanced Cancers
|
Phase 1 | |
Completed |
NCT00389480 -
Study of AR-67 (Formerly DB-67) in Adult Patients With Refractory or Metastatic Solid Malignancies
|
Phase 1 |